Current Edition

COVID-19

Novavax, fashionably late to the COVID-19 vaccine party, could still reap $5B in 2022: analyst

After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax’s program could be destined to reap billions of dollars …

Continue Reading →